Jefferies Reiterates Buy Rating on Amedisys (AMED) But Says Q3 Numbers 'Need to Come Down'
Tweet Send to a Friend
Jefferies analyst Brian Tanquilut reiterated a Buy rating and $200.00 price target on Amedisys (NASDAQ: AMED), but said while FY22 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
